Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v2.4.0.6
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2012
Dec. 31, 2011
Current assets:    
Cash $ 18,102 $ 5,406
Receivables 4,646 3,720
Prepaid expenses and other current assets 687 836
Total current assets 23,435 9,962
Property and equipment, net 1,392 255
Total Assets 24,827 10,217
Current liabilities:    
Accounts payable 3,767 4,789
Accrued clinical trials expenses 532 161
Other accrued liabilities 219 173
Deferred contract revenue 14,375 0
Current portion of long-term debt 2,500 0
Total current liabilities 21,393 5,123
Warrant liability 8,240 3,611
Accrued Royalties Current and Noncurrent 8,962 9,309
Long-term debt, net of discount 9,360 12,253
Total Liabilities 47,955 30,296
Commitments and contingencies      
Stockholders' deficit:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding: 0 0
Common stock, at amounts paid in, $0.001 par value per share; 125,000,000 shares authorized, 75,215,713 and 59,386,542 shares issued and outstanding at December 31, 2012 and 2011, respectively. 265,986 256,436
Additional paid-in capital 21,014 18,433
Accumulated deficit (310,128) (294,948)
Total stockholders' deficit (23,128) (20,079)
Total Liabilities and Stockholders Deficit $ 24,827 $ 10,217